Company profile

NEUROCRINE BIOSCIENCES INC

NASDAQ:NBIXBiotechnology: Biological Products (No Diagnostic Substances)

Drug pipeline (11)

Asset	Stage	Revenue	Trials	Status
Crinecerfont	approved	—	6	approved
Valbenazine tosylate	approved	—	0	—
Direclidine	phase3	—	6	active
INDIPLON	phase3	—	1	withdrawn
Valbenazine	phase3	—	12	completed, terminated

Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.

Clinical trials (101)

NCT ID	Phase	Status	Start	Completion	Sponsor name	Title
NCT02274558	phase3	completed	2014-10-01	2015-09-01	Neurocrine Biosciences	A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
NCT03319953	phase2	completed	2017-12-21	2019-09-11	Neurocrine Biosciences	A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizophrenia
NCT02959892	phase1	completed	2016-12-05	2017-05-30	Neurocrine Biosciences	A Single-Dose Positron Emission Tomography (PET) Study to Determine the Effect of TAK-041 on Amphetamine-Induced Dopamine Release in the Central Nervous System (CNS)
NCT03343327	phase1	completed	2018-02-19	2018-04-20	Neurocrine UK Limited	A Study of Chronocort® Versus Cortef ® in Healthy Adult Male Subjects
NCT03311932	phase1	completed	2018-04-16	2018-07-13	Neurocrine UK Limited	A Study of Infacort® Versus Cortef® in Healthy Adult Male and Female Subjects

FDA applications (4)

Application

Type

Applicant

Products

NDA 209241

NDA

NEUROCRINE BIOSCIENCES INC

NDA 218390

NDA

NEUROCRINE BIOSCIENCES INC

NDA 218808

NDA

NEUROCRINE BIOSCIENCES INC

NDA 218820

NDA

NEUROCRINE BIOSCIENCES INC